EXPRESSION OF SERUM GFAP AND IGF-1 IN GLIOMA AND ITS RELATIONSHIP WITH CLINICOPATHOLOGICAL PROGNOSIS

Objective: To investigate the expression of serum glial fibrillary acidic protein (GFAP) and insulin-like growth factor-1 (IGF-1) in brain glioma and its correlation with clinicopathological prognosis. Methods: A retrospective analysis was performed on 74 patients with glioma admitted to our hospital from April 2014 to May 2015. These patients were selected as the observation group, and 67 healthy patients in our hospital were selected as the control group. All patients in the observation group were treated with surgery combined with chemoradiotherapy. The levels of GFAP and IGF-1 in the control group were compared on the day of physical examination and in the observation group before and after 1w as well as after chemoradiotherapy. According to the survival time of glioma patients, the patients were divided into 27 patients with good prognosis and 47 patients with poor prognosis. GFAP and IGF-1 levels were compared between the two groups. Patients were divided into a complete remission group, a partial remission group, a stable group and a progressive group according to the efficacy evaluation criteria of solid tumours. GFAP and IGF-1 levels were compared in each group. An ROC curve was drawn to analyse the diagnostic value of GFAP and IGF-1 in the prognosis of glioma. Results: In comparison with the control group, GFAP and IGF-1 levels were significantly higher in the observation group at all time periods (P<0.05). Compared with the preoperative level, the GFAP and IGF-1 levels in the observation group were significantly decreased 1w after surgery and after chemoradiotherapy (P<0.05). Compared with 1w after surgery, GFAP and IGF-1 levels in the observation group after radiotherapy and chemotherapy were significantly reduced (P<0.05). Compared with the group having a good prognosis, GFAP and IGF-1 in the group with poor prognosis were significantly increased (P<0.05). Compared with the complete remission group, the GFAP and IGF-1 levels of patients in the partial remission group, stable group and progressive group were significantly increased. GFAP and IGF-1 levels were significantly higher than those in the stable group and the progressive group (P<0.05). The area under the GFAP and IGF-1 curves were 0.842 and 0.955, the specificity was 87.70% and 92.30%, and the sensitivity was 82.50% and 90.00%, respectively. Conclusion: The expression levels of GFAP and IGF-1 in the serum of glioma patients were significantly increased, and both can be used as reference indexes for evaluating the prognosis of glioma patients, which is conducive to improving diagnostic efficiency and accuracy.